tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Quantum BioPharma Receives Health Canada Approval for Qlarity

Story Highlights
Quantum BioPharma Receives Health Canada Approval for Qlarity

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Quantum Biopharma ( (TSE:QNTM) ) just unveiled an update.

On September 18, 2025, Quantum BioPharma announced that Health Canada has granted a Product License for its natural health product, Qlarity, which enhances energy, metabolism, mental alertness, and cognitive performance. This approval allows Quantum to sell Qlarity in Canada, marking a significant milestone in its mission to bring innovative products to market. The license is expected to positively impact Quantum’s operations by expanding its market reach and enhancing its industry positioning.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is engaged in research and development through its subsidiary, Lucid Psycheceuticals Inc., and holds a strategic investment portfolio through FSD Strategic Investments Inc.

Average Trading Volume: 4,971

Technical Sentiment Signal: Hold

Current Market Cap: C$94.44M

See more insights into QNTM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1